A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy

  • Cancer
  • Lung Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • China
  • Malaysia
  • Singapore
  • South Korea
  • Thailand
Trial Identifier:

NCT02813785 YO29232

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This Phase III, multicenter, open-label, randomized, controlled study is designed to evaluate the efficacy and safety of the anti-programmed death-ligand 1 (PD-L1) antibody atezolizumab compared with docetaxel in participants with locally advanced or metastatic NSCLC who have progressed during or following a platinum-containing regimen. Treatment may continue until disease progression, loss of clinical benefit, or unacceptable toxicity.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT02813785,YO29232 Trial Identifier
      Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Docetaxel Treatments
      Carcinoma, Non-Small-Cell Lung Condition
      Official Title

      A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Histologically documented, locally advanced or metastatic NSCLC
      • Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens available or at least 12 unstained, freshly cut serial sections with associated pathology report that are evaluable for PD-L1 expression and epidermal growth factor receptor (EGFR) mutation status prior to enrollment, except for known sensitizing EGFR mutations in which case 10 unstained slides are required and there is no need for central testing of EGFR mutation status
      • Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable, inoperable, or metastatic NSCLC, or disease recurrence within 6 months of treatment with a platinum-based adjuvant and/or neoadjuvant regimen or combined modality with curative intent
      • Measurable disease per RECIST v1.1
      • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
      • Life expectancy greater than or equal to (>/=) 12 weeks
      • Adequate hematologic and end organ function
      • Agreement to remain abstinent or use contraceptive methods among women of childbearing potential or male partners of women of childbearing potential
      • Recovery from all acute toxicities from previous therapy
      Exclusion Criteria
      • Active or untreated central nervous system (CNS) metastases
      • Spinal cord compression not definitively treated or not clinically stable
      • Leptomeningeal disease
      • Uncontrolled pleural or pericardial effusions or ascites requiring recurrent drainage
      • Uncontrolled tumor-related pain
      • Uncontrolled hypercalcemia
      • Malignancies other than NSCLC within 5 years prior to randomization, except for those curatively treated with negligible risk of metastasis or death
      • Pregnant or lactating women
      • Significant cardiovascular, pulmonary, or autoimmune disease
      • Severe infection or major surgery within 4 weeks, or antibiotic treatment within 2 weeks prior to randomization
      • Prior treatment with or hypersensitivity to study drug(s) or related compounds
      • Inability to discontinue strong cytochrome P450 (CYP) 3A4 inhibitors
      • Prior allogeneic bone marrow or solid organ transplant
      • Known PD-L1-negative expression status
      • Positive human immunodeficiency virus (HIV) or active hepatitis B or C
      • Receipt of a live attenuated vaccine within 4 weeks prior to randomization
      • Treatment with systemic immunomodulators within 4 weeks or five half-lives (whichever is shorter) prior to randomization
      • Treatment with systemic corticosteroids within 2 weeks prior to randomization

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now